BACE1 and Alzheimer disease: The concept of BACE‐1 inhibition for the treatment of AD has gained significant momentum since the identification of low‐molecular‐weight, highly potent and brain‐penetrating compounds derived from a cyclic amidine core structure (Zhu et al, 2010), such as CNP520.